Huang Hongyan, Mo Junyang, Ding Zhiguang, Peng Xuehua, Liu Ruihao, Zhuang Danping, Zhang Yuzhong, Hu Genwen, Huang Bingsheng, Qiu Yingwei
From the Department of Radiology, Shenzhen Nanshan People's Hospital, Shenzhen University, Taoyuan Rd No. 89, Nanshan District, Shenzhen 518000, Guangdong, China (H.H., Z.D., Y.Q.); Medical AI Laboratory and Guangdong Key Laboratory of Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, China (J.M., R.L., B.H.); Department of Medical Imaging, People's Hospital of Longhua, Shenzhen, Guangdong, China (X.P., Y.Z.); and Department of Radiology, Shenzhen People's Hospital, Shenzhen, Guangdong, China (D.Z., G.H.).
Radiology. 2025 Jan;314(1):e240238. doi: 10.1148/radiol.240238.
Background Multiparametric MRI, including contrast-enhanced sequences, is recommended for evaluating suspected prostate cancer, but concerns have been raised regarding potential contrast agent accumulation and toxicity. Purpose To evaluate the feasibility of generating simulated contrast-enhanced MRI from noncontrast MRI sequences using deep learning and to explore their potential value for assessing clinically significant prostate cancer using Prostate Imaging Reporting and Data System (PI-RADS) version 2.1. Materials and Methods Male patients with suspected prostate cancer who underwent multiparametric MRI were retrospectively included from three centers from April 2020 to April 2023. A deep learning model (pix2pix algorithm) was trained to synthesize contrast-enhanced MRI scans from four noncontrast MRI sequences (T1-weighted imaging, T2-weighted imaging, diffusion-weighted imaging, and apparent diffusion coefficient maps) and then tested on an internal and two external datasets. The reference standard for model training was the second postcontrast phase of the dynamic contrast-enhanced sequence. Similarity between simulated and acquired contrast-enhanced images was evaluated using the multiscale structural similarity index. Three radiologists independently scored T2-weighted and diffusion-weighted MRI with either simulated or acquired contrast-enhanced images using PI-RADS, version 2.1; agreement was assessed with Cohen κ. Results A total of 567 male patients (mean age, 66 years ± 11 [SD]) were divided into a training test set ( = 244), internal test set ( = 104), external test set 1 ( = 143), and external test set 2 ( = 76). Simulated and acquired contrast-enhanced images demonstrated high similarity (multiscale structural similarity index: 0.82, 0.71, and 0.69 for internal test set, external test set 1, and external test set 2, respectively) with excellent reader agreement of PI-RADS scores (Cohen κ, 0.96; 95% CI: 0.94, 0.98). When simulated contrast-enhanced imaging was added to biparametric MRI, 34 of 323 (10.5%) patients were upgraded to PI-RADS 4 from PI-RADS 3. Conclusion It was feasible to generate simulated contrast-enhanced prostate MRI using deep learning. The simulated and acquired contrast-enhanced MRI scans exhibited high similarity and demonstrated excellent agreement in assessing clinically significant prostate cancer based on PI-RADS, version 2.1. © RSNA, 2025 See also the editorial by Neji and Goh in this issue.
多参数磁共振成像(MRI),包括对比增强序列,被推荐用于评估疑似前列腺癌,但人们对潜在的对比剂蓄积和毒性表示担忧。目的:评估使用深度学习从非对比MRI序列生成模拟对比增强MRI的可行性,并使用前列腺影像报告和数据系统(PI-RADS)2.1版探索其在评估临床显著性前列腺癌方面的潜在价值。材料与方法:回顾性纳入2020年4月至2023年4月在三个中心接受多参数MRI检查的疑似前列腺癌男性患者。训练一个深度学习模型(pix2pix算法),以从四个非对比MRI序列(T1加权成像、T2加权成像、扩散加权成像和表观扩散系数图)合成对比增强MRI扫描,然后在一个内部数据集和两个外部数据集上进行测试。模型训练的参考标准是动态对比增强序列的第二个对比剂注射后阶段。使用多尺度结构相似性指数评估模拟和采集的对比增强图像之间的相似性。三名放射科医生使用PI-RADS 2.1版对T2加权和扩散加权MRI的模拟或采集的对比增强图像进行独立评分;使用Cohen κ评估一致性。结果:总共567名男性患者(平均年龄,66岁±11[标准差])被分为训练测试集(n = 244)、内部测试集(n = 104)、外部测试集1(n = 143)和外部测试集2(n = 76)。模拟和采集的对比增强图像显示出高度相似性(内部测试集、外部测试集1和外部测试集2的多尺度结构相似性指数分别为0.82、0.71和0.69),PI-RADS评分的阅片者一致性良好(Cohen κ,0.96;95%可信区间:0.94,0.98)。当将模拟对比增强成像添加到双参数MRI中时,323例患者中有34例(10.5%)从PI-RADS 3级升级到PI-RADS 4级。结论:使用深度学习生成模拟对比增强前列腺MRI是可行的。模拟和采集的对比增强MRI扫描显示出高度相似性,并且在基于PI-RADS 2.1版评估临床显著性前列腺癌方面表现出良好的一致性。©RSNA,2025 另见本期Neji和Goh的社论。